Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil Wolsk

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Journal of the American Heart Association|July 19, 2021
Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE TrialMikkel Jürgens, Morten Schou, Philip Hasbak, et al.
Journal of Cardiac Failure|November 26, 2018
Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy HumansEmil Wolsk, Rine Bakkestrøm, Charlotte Burup Kristensen, et al.
BMC Geriatrics|March 22, 2022
Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study)Saaima Parveen, Bochra Zareini, Anojhaan Arulmurugananthavadivel, et al.
BMJ Open|November 30, 2019
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)Mikkel Jürgens, Morten Schou, Philip Hasbak, et al.
Diabetes|January 21, 2022
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE TrialEmil Wolsk, Mikkel Jürgens, Morten Schou, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trialHertzel C Gerstein, Emil Wolsk, Brian Claggett, et al.
JACC. Heart Failure|March 11, 2019
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection FractionEmil Wolsk, David Kaye, Jan Komtebedde, et al.
JACC. Heart Failure|July 8, 2026
Medium-Chain Triacylglycerol Improves Cardiac Function in Chronic Heart Failure: A Randomized Cross-Over TrialJosephine M Kanta, Amalie S Frederiksen, Amalie London, et al.
Cardiovascular Diabetology|October 13, 2020
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trialMagnus O Wijkman, Brian Claggett, Rafael Diaz, et al.
Circulation|October 18, 2017
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes MellitusEmil Wolsk, Brian Claggett, Rafael Diaz, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of the American Heart Association|July 19, 2021
Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE TrialMikkel Jürgens, Morten Schou, Philip Hasbak, et al.
Journal of Cardiac Failure|November 26, 2018
Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy HumansEmil Wolsk, Rine Bakkestrøm, Charlotte Burup Kristensen, et al.
BMC Geriatrics|March 22, 2022
Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study)Saaima Parveen, Bochra Zareini, Anojhaan Arulmurugananthavadivel, et al.
BMJ Open|November 30, 2019
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)Mikkel Jürgens, Morten Schou, Philip Hasbak, et al.
Diabetes|January 21, 2022
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE TrialEmil Wolsk, Mikkel Jürgens, Morten Schou, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trialHertzel C Gerstein, Emil Wolsk, Brian Claggett, et al.
JACC. Heart Failure|March 11, 2019
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection FractionEmil Wolsk, David Kaye, Jan Komtebedde, et al.
JACC. Heart Failure|July 8, 2026
Medium-Chain Triacylglycerol Improves Cardiac Function in Chronic Heart Failure: A Randomized Cross-Over TrialJosephine M Kanta, Amalie S Frederiksen, Amalie London, et al.
Cardiovascular Diabetology|October 13, 2020
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trialMagnus O Wijkman, Brian Claggett, Rafael Diaz, et al.
Circulation|October 18, 2017
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes MellitusEmil Wolsk, Brian Claggett, Rafael Diaz, et al.
Pageof 6